Sigma share price drops after shareholders vote on Chemist Warehouse merger

The results are in.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Sigma Healthcare Ltd (ASX: SIG) share price is falling after the company released the results of last night's shareholder vote on the proposed merger with Chemist Warehouse.

The Sigma share price is 2.64% lower at $2.95 at the time of writing.

The ASX 200 healthcare stock opened at $3.10 per share, up 2.3% on yesterday's closing price.

But it reversed course quickly and tumbled into the red within the first 15 minutes of trading.

Let's check out the details of the vote.

A company manager presents the ASX company earnings report to shareholders at an AGM.

Image source: Getty Images

Sigma share price down despite merger approval

Sigma shareholders voted overwhelmingly in favour of the proposed merger with CW Group Holdings Limited at last night's meeting in Melbourne.

In a statement released to the market last night, Sigma said the merger received 99.86% approval from shareholders.

Four Chemist Warehouse executives were elected to the Sigma Healthcare board.

Chemist Warehouse co-founder and board chair Jack Gance received 91.92% support to become a non-executive director.

Chemist Warehouse's CEO Mario Verrocchi, Chief Property Officer Damien Gance, and Chief People Officer Danielle Di Pilla each received more than 97% support to become executive directors.

In an address before the Sigma shareholders' vote, Sigma chair Michael Sammells said the merger would accelerate Sigma's strategic direction "by bringing together two complementary businesses with complementary core strengths and expertise to enhance our service offering to customers".

He said:

Sigma has world-class distribution infrastructure and capability that is delivering best in class service
to pharmacies across Australia every day.

Chemist Warehouse has unparalleled pharmacy franchise and marketing know-how and expertise which will also help elevate our support for our Amcal and Discount Drug Store franchisees.

Given the nature and value accretion of the proposed transaction, Sigma Directors unanimously recommend that Shareholders vote in favour of the Resolutions.

Sammells said the merger would create a wide range of growth opportunities in Australia and overseas.

Following the Sigma shareholders' vote, a scheme meeting and vote were conducted among Chemist Warehouse shareholders.

The merger received 99.23% support at that meeting.

What's next?

The scheme is now subject to court approval next Monday, 3 February, in Melbourne.

If approved, Chemist Warehouse will lodge the orders of the court with the Australian Securities and Investments Commission (ASIC) the following day.

This will make the scheme legally effective and binding on Chemist Warehouse shareholders.

The indicative date for implementation of the transaction is 12 February.

New Sigma shares issued under the scheme are expected to commence trading on a normal settlement basis on 13 February.

Broker downgrades Sigma shares

According to The Australian, Ord Minnett has cut its rating on Sigma shares to a hold.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Silver dice with buy and sell written on them on top of stock market charts.
Healthcare Shares

CSL shares have surged 49%: Are brokers finally turning bullish?

CSL’s recovery is gathering pace, but has the share price already priced in the turnaround?

Read more »

a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.
Healthcare Shares

Clarity Pharmaceuticals FY26 earnings: Revenue jumps, losses widen as clinical pipeline progresses

Clarity Pharmaceuticals reported strong FY26 revenue growth, a wider loss, and progress towards commercialisation of its radiopharmaceutical pipeline.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Clinuvel Pharmaceuticals posts 10th consecutive profit and maintains dividend

Clinuvel Pharmaceuticals reported its tenth straight profit, rising cash reserves, and steady dividend for FY2026.

Read more »

Man and woman sitting at table with the man looking a bit puzzled at his laptop.
Healthcare Shares

Should I buy CSL shares before the end of August?

I think the company's earnings outlook is starting to look more encouraging.

Read more »

Female pharmacist smiles with a digital tablet.
Earnings Results

Sigma Healthcare FY26 earnings: Record profit as Chemist Warehouse merger delivers growth

The company reported double-digit revenue growth.

Read more »

Health professional working on his laptop.
Earnings Results

Mesoblast earnings: Strong revenue growth and operational milestones in FY26

The biotech has reported a significant jump in revenue.

Read more »

Two lab workers fist pump each other.
Earnings Results

Ramsay Health Care FY26: Profit surges on transformation momentum

The results show stronger profit growth, a higher dividend, and continued momentum in its transformation plans.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Starpharma: FY26 earnings reveal strong revenue growth and improved loss

Starpharma posted a sharp rise in FY26 revenue and narrowed its loss, with new funds extending its cash runway into…

Read more »